Vimalanand Shrikant Prabhu

9PUBLICATIONS
12CO-AUTHORS
Epidemiological modellingPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Preventative health careMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 22, 2024
Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study.

Vimalanand S Prabhu, Kalé Kponee-Shovein, Mu Cheng

|Apr 18, 2024
Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe.

Sneha S Kelkar, Vimalanand S Prabhu, Jingchuan Zhang

|Mar 12, 2024
Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.

Lewis Ralph, Kate Young, Navneet Upadhyay

|Oct 13, 2023
Real-world utilization of lenvatinib and pembrolizumab combination therapy for the treatment of endometrial cancer in the USA.

Keiko Wada, Jingchuan Zhang, Inyoung Lee

|Sep 07, 2021
HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States.

Vimalanand S Prabhu, Neha Bansal, Zhiwen Liu

|May 21, 2021
Incremental healthcare resource utilization and costs for patients with cervical, vaginal, vulvar, anal, and oropharyngeal cancer in the United States.

Vimalanand Prabhu, Niranjan Kathe, Kunal Saxena

Pageof 2

Frequent Collaborators

1 joint publications

Niranjan Kathe

1 joint publications

Evan Myers

1 joint publications

Mark Einstein

1 joint publications

Inyoung Lee